There has been little progress in the search for cures for the aggressive brain cancer glioblastoma, largely because of a lack of understanding of how the tumor cells interact with the immune system and other cells and tissues in the body. A new glioblastoma map was designed to fill in some of those knowledge gaps.

The invasiveness and high immune suppression of glioblastoma multiforme (GBM) produce poor survival of afflicted patients. Unfortunately, in the past decades, no therapeutic approach has remarkably improved the survival time of patients with GBM.

The first patient has been dosed in a Phase 2 trial assessing the safety and preliminary efficacy of PVSRIPO in combination with Keytruda (pembrolizumab) as a treatment for people with recurrent glioblastoma multiforme (rGBM), an aggressive form of brain cancer.

The February issue of Neurosurgical Focus examines the use of viral vector–mediated gene therapy in the treatment of glioblastoma multiforme (GBM).

The FDA granted fast track designation to GLR2007 for treatment of glioblastoma, according to the agent’s manufacturer.

Breakthrough Science to Treat Colon Cancer and Glioblastoma was presented via Hidden GEMS Program from One Million Solutions in Health